Sugi Predict

Sugi Predict / Compounds / SCHEMBL2302595

SCHEMBL2302595

SCHEMBL2302595

CC(C)(C)OC(=O)N1C2CCC1CN(c1ccc([N+](=O)[O-])nc1)C2

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.54
▸ RAB9A P51151 1/20 0.53
▸ GPR119 Q8TDV5 3/20 0.48
▸ HSD11B1 P28845 1/20 0.47
▸ CHRNB2 P17787 3/20 0.46
▸ CHRNA4 P43681 3/20 0.46
▸ CHRNB4 P30926 2/20 0.46
▸ CHRNA3 P32297 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ POLB P06746 1/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ JAK1 P23458 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31106300 1.00 MAPT (0.54) MAPTRAB9AGPR119HSD11B1CHRNB2
SCHEMBL31173940 0.96 MAPT (0.52) MAPTRAB9AGPR119HSD11B1CHRNB2
SCHEMBL25189494 0.96 MAPT (0.52) MAPTRAB9AGPR119HSD11B1CHRNB2
SCHEMBL29891172 0.94 MAPT (0.57) MAPTRAB9AGPR119HSD11B1CHRNB2
SCHEMBL30630192 0.94 MAPT (0.57) MAPTRAB9AGPR119HSD11B1CHRNB2
SCHEMBL18823184 0.88 MAPT (0.58) MAPTRAB9AGPR119CHRNB2CHRNA4
SCHEMBL30427113 0.88 MAPT (0.58) MAPTRAB9AGPR119CHRNB2CHRNA4
SCHEMBL15011765 0.87 HSD11B1 (0.44) MAPTRAB9AGPR119HSD11B1CHRNB2
SCHEMBL2299688 0.87 HSD11B1 (0.44) MAPTRAB9AGPR119HSD11B1CHRNB2
SCHEMBL2305824 0.87 HSD11B1 (0.44) MAPTRAB9AGPR119HSD11B1CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 — — EP disclosed
US-12215105-B2 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2025-02-04 — — US disclosed
US-20250026753-A1 FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024238793-A1 FUSED TRIAZINONES FOR USE IN THE TREATMENT OF CANCER RGENTA THERAPEUTICS, INC. (US) 2024-11-21 — — WO disclosed
CN-118871445-A Fused triazinone derivatives and methods of use thereof 亚根达医疗公司 2024-10-29 — — CN disclosed
CN-111333627-B Substituted 2-hydro-pyrazole derivatives as anticancer agents 正大天晴药业集团股份有限公司 2024-09-13 — — CN disclosed
WO-2024173646-A1 CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-08-22 — — WO disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
WO-2023086959-A1 FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. (US) 2023-05-19 — — WO disclosed
US-8957074-B2 Pyrrolopyrimidine compounds as inhibitors of CDK4/6 NOVARTIS AG (CH) 2015-02-17 — — US disclosed
US-20130150342-A1 PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 NOVARTIS AG (CH) 2013-06-13 — — US disclosed
US-20130150342-A1 PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 NOVARTIS AG (CH) 2013-06-13 — — US disclosed
EP-2536730-A1 PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 Novartis AG (CH) 2012-12-26 — — EP disclosed
WO-2011101409-A1 PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 NOVARTIS AG (CH) 2011-08-25 — — WO disclosed
EP-1359152-B1 Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands ABBOTT LAB (US) 2008-05-07 — — EP disclosed
US-7265115-B2 Diazabicyclic CNS active agents ABBOTT LABORATORIES (US) 2007-09-04 — — US disclosed
US-20030225268-A1 Diazabicyclic CNS active agents ABBVIE INC. 2003-12-04 — — US disclosed
EP-1359152-A2 Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands ABBOTT LABORATORIES (US) 2003-11-05 — — EP disclosed
EP-1147112-B1 DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ABBOTT LAB (US) 2003-10-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 MAPT 3895/4885RAB9A 2937/4885GPR119 380/4885
US-20130150342-A1 PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 CDK4, CDK6, CCNT1 MAPT 3975/4885RAB9A 1584/4885GPR119 2573/4885
US-20030225268-A1 Diazabicyclic CNS active agents GABRE, GRIN1, CNTN1 MAPT 2125/4885RAB9A 579/4885GPR119 343/4885
US-20250026753-A1 FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME SF3B5, RBM17, SF3A2 MAPT 4400/4885RAB9A 3009/4885GPR119 1827/4885
US-12215105-B2 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 MAPT 3895/4885RAB9A 2937/4885GPR119 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.